Investor Expectations to Drive Momentum within Materialise

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
67
Investor Expectations to Drive Momentum within Materialise NV, Southern First Bancshares, Ensco plc, Corbus Pharmaceuticals, TCP Capital, and Horizon Pharma Public — Discovering Underlying Factors of Influence

NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Materialise NV (NASDAQ: MTLS ), Southern First Bancshares, Inc. (NASDAQ: SFST ), Ensco plc (NYSE: ESV ), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP ), TCP Capital Corp. (NASDAQ: TCPC ), and Horizon Pharma Public Limited Company (NASDAQ: HZNP ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

MTLS DOWNLOAD: http://Fundamental-Markets.com/register/?so=MTLS SFST DOWNLOAD: http://Fundamental-Markets.com/register/?so=SFST ESV DOWNLOAD: http://Fundamental-Markets.com/register/?so=ESV CRBP DOWNLOAD: http://Fundamental-Markets.com/register/?so=CRBP TCPC DOWNLOAD: http://Fundamental-Markets.com/register/?so=TCPC HZNP DOWNLOAD: http://Fundamental-Markets.com/register/?so=HZNP

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Materialise NV (NASDAQ: MTLS ), Southern First Bancshares, Inc. (NASDAQ: SFST ), Ensco plc (NYSE: ESV ), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP ), TCP Capital Corp. (NASDAQ: TCPC ), and Horizon Pharma Public Limited Company (NASDAQ: HZNP ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed August 17th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

MATERIALISE NV (MTLS) REPORT OVERVIEW

Materialise NV's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Materialise NV reported revenue of $53.76MM vs $38.36MM (up 40.15%) and basic earnings per share $0.01 vs -$0.02. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Materialise NV reported revenue of $161.15MM vs $126.68MM (up 27.21%) and basic earnings per share -$0.03 vs -$0.07. Materialise NV is expected to report earnings on November 8th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.04. The estimated EPS forecast for the next fiscal year is $0.25 and is expected to report on March 5th, 2019.

To read the full Materialise NV (MTLS) report, download it here: http://Fundamental-Markets.com/register/?so=MTLS

-----------------------------------------

SOUTHERN FIRST BANCSHARES, INC. (SFST) REPORT OVERVIEW

Southern First Bancshares' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Southern First Bancshares reported interest income of $18.54MM vs $14.93MM (up 24.14%) and basic earnings per share $0.75 vs $0.52 (up 44.23%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Southern First Bancshares reported interest income of $61.21MM vs $51.19MM (up 19.57%) and basic earnings per share $1.86 vs $2.06 (down 9.71%). Southern First Bancshares is expected to report earnings on August 21st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.49.

To read the full Southern First Bancshares, Inc. (SFST) report, download it here: http://Fundamental-Markets.com/register/?so=SFST

-----------------------------------------

ENSCO PLC (ESV) REPORT OVERVIEW

Ensco plc's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Ensco plc reported revenue of $458.50MM vs $457.50MM (up 0.22%) and basic earnings per share -$0.35 vs -$0.15. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Ensco plc reported revenue of $1,843.00MM vs $2,776.40MM (down 33.62%) and basic earnings per share -$0.91 vs $3.13. Ensco plc is expected to report earnings on October 24th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.05. The estimated EPS forecast for the next fiscal year is -$1.16 and is expected to report on February 25th, 2019.

To read the full Ensco plc (ESV) report, download it here: http://Fundamental-Markets.com/register/?so=ESV

-----------------------------------------

CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) REPORT OVERVIEW

Corbus Pharmaceuticals' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Corbus Pharmaceuticals reported revenue of $0.85MM vs $0.35MM (up 143.75%) and basic earnings per share -$0.21 vs -$0.15. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Corbus Pharmaceuticals reported revenue of $2.44MM vs $1.91MM (up 27.67%) and basic earnings per share -$0.65 vs -$0.49. Corbus Pharmaceuticals is expected to report earnings on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$0.94 and is expected to report on March 11th, 2019.

To read the full Corbus Pharmaceuticals Holdings, Inc. (CRBP) report, download it here: http://Fundamental-Markets.com/register/?so=CRBP

-----------------------------------------

TCP CAPITAL CORP. (TCPC) REPORT OVERVIEW

TCP Capital's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, TCP Capital reported revenue of $48.42MM vs $46.23MM (up 4.74%) and basic earnings per share $0.07 vs $0.35 (down 80.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, TCP Capital reported revenue of $175.97MM vs $148.18MM (up 18.75%) and basic earnings per share $1.19 vs $1.50 (down 20.67%). TCP Capital is expected to report earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.38. The estimated EPS forecast for the next fiscal year is $1.60 and is expected to report on February 26th, 2019.

To read the full TCP Capital Corp. (TCPC) report, download it here: http://Fundamental-Markets.com/register/?so=TCPC

-----------------------------------------

HORIZON PHARMA PUBLIC LIMITED COMPANY (HZNP) REPORT OVERVIEW

Horizon Pharma Public's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Horizon Pharma Public reported revenue of $302.84MM vs $289.51MM (up 4.60%) and basic earnings per share -$0.20 vs -$1.29. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Horizon Pharma Public reported revenue of $1,056.23MM vs $981.12MM (up 7.66%) and basic earnings per share -$2.52 vs -$1.04. Horizon Pharma Public is expected to report earnings on November 5th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.26. The estimated EPS forecast for the next fiscal year is $1.86 and is expected to report on February 27th, 2019.

To read the full Horizon Pharma Public Limited Company (HZNP) report, download it here: http://Fundamental-Markets.com/register/?so=HZNP

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 35

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 51

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 291

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 595

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 0

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Reactions: Middle East Tensions and the Vance-Walz Debate

Updated Category News Views 71

Market Reactions to Middle East Tensions US stock futures are experiencing a downward trend as investors react to the escalating violence in the Middle East. With Iran claiming to have ceased its air bombardments on Israel, uncertainty still looms, as Israeli officials pledge a counterattack. This ongoing conflict has already impacted Wall Street, where equity values...

Continue Reading
Class Action Alert for Visa Inc. Shareholders Facing Losses

Updated Category News Views 91

Class Action Notification for Visa Inc. Shareholders The Gross Law Firm is reaching out to shareholders of Visa Inc. (NYSE: V) regarding an important class action that may affect them. If you purchased shares during a specific class period and have suffered losses, your participation could be significant in holding the company accountable. Understanding the Class Period...

Continue Reading
Coca-Cola's Earnings Report: Anticipated Insights and Analysis

Updated Category News Views 205

Coca-Cola's Earnings Report Overview The Coca-Cola Company (NYSE: KO) is on the cusp of unveiling its second-quarter financial results. Investors, analysts, and fans alike are closely watching what insights the beverage giant will provide during this crucial report. With notable figures in the U.S. market keeping an eye on Coca-Cola, the anticipation is palpable. Earnings...

Continue Reading
Maggiano's Unveils Gourmet Italian-American Classics Menu

Updated Category News Views 410

Introduction of Italian-American Classics at Maggiano's Maggiano's Little Italy is embracing the culinary heritage of Italian-American cuisine by introducing a new menu that reflects a dedication to high-quality ingredients and gourmet recipes. Under the expert guidance of award-winning Chef Anthony Amoroso, the restaurant's latest offerings promise to impress food...

Continue Reading
Recognizing Excellence: Pierce & O'Neill Founders Honored

Updated Category News Views 362

Pierce & O’Neill Founders Honored Among Top Attorneys Pierce & O’Neill, LLP, a renowned litigation boutique, is celebrating its founders, Jesse Pierce and Jack O’Neill, for their remarkable achievements in the legal field. Recently recognized in Lawdragon’s prestigious list of the 500 Leading Lawyers in America for 2025, this accolade showcases their exceptional...

Continue Reading